title: Relationship between the area of isopters and Vigabatrin dosage during two years of observation.
abstract: BACKGROUND
  The aim of the study was to evaluate the relationship between the area of isopters obtained using semi-automated kinetic perimetry (SKP) and Vigabatrin dosage in epilepsy patients with pretreatment baseline examination during 2-years of the follow-up.
  
  
  METHODS
  29 epilepsy patients were included into the study, but 15 individuals were excluded due to cognitive impairment, intracranial pathologies or eye diseases. Finally, 14 patients were examined with SKP before VGB treatment and after 6, 12, 18, and 24 months. Reaction time (RT)-corrected areas of three isopters (III4e, I4e and I2e) were measured for each of five examinations and compared intra-individually during 2-years period. Additionally, six epilepsy patients on other antiepileptic drugs were examined five times with SKP as a control.
  
  
  RESULTS
  There was a significant decrease of I2e, I4e and III4e isopters' area during the follow-up of two years. Correlation was found between the I2e isopter's area and both cumulative dose and mean daily dose of VGB. With increasing RT, there was decreasing of all isopters' area in patients receiving VGB. In epilepsy patients who were not receiving VGB, there were no significance differences in isopters' area during follow-up.
  
  
  CONCLUSIONS
  There was attenuation of area of III4e, I4e and I2e isopters obtained with SKP during a period of 2 years. RT, the cumulative dose and the mean daily dose of VGB influenced isopters' area obtained with SKP.
authors.affiliation: Department of General Ophthalmology, Medical University, ul, Chmielna 1, 20-079 Lublin, Poland. katarzynanowomiejska@mailcity.com.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Nowomiejska
authors.forename: Marian
authors.initials: M
authors.lastname: Jedrych
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Brzozowska
authors.forename: Konrad
authors.initials: K
authors.lastname: Rejdak
authors.forename: Tomasz
authors.initials: T
authors.lastname: Zarnowski
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Koss
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Ksiazek
authors.forename: Piotr
authors.initials: P
authors.lastname: Ksiazek
authors.forename: Ryszard
authors.initials: R
authors.lastname: Maciejewski
authors.forename: Anselm G
authors.initials: AG
authors.lastname: Juenemann
authors.forename: Ulrich
authors.initials: U
authors.lastname: Schiefer
authors.forename: Robert
authors.initials: R
authors.lastname: Rejdak
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009901:Optic Nerve Diseases / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology; D011044:Poland / Q000453:epidemiology; D011446:Prospective Studies; D012307:Risk Factors; D012607:Scotoma / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D013997:Time Factors; D020888:Vigabatrin / Q000008:administration & dosage*; D058609:Visual Field Tests; D014794:Visual Fields / Q000187:drug effects*; D055815:Young Adult
chemical_list: D000927:Anticonvulsants; D020888:Vigabatrin